Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
PR Newswire•02/11/2026•16:05 ET
0
Key Highlights
- ➤3Q26 revenue $1.243B, up 10% year over year
- ➤2026 revenue guidance raised to $4.775-$4.85B
- ➤Xywav sales rose 12% to $483M, adding 425 net patients
- ➤Ziihera launched for first-line HER2-positive GEA after FDA approval
- ➤Actio acquisition added ABS-1230 to Jazz’s rare-epilepsy portfolio
Expert Statements
Renee Gala, President and Chief Executive Officer of Jazz Pharmaceuticals
“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance.”
Renee Gala, President and Chief Executive Officer of Jazz Pharmaceuticals
“At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies.”
Renee Gala, President and Chief Executive Officer of Jazz Pharmaceuticals
“Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders.”
Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results PR Newswire
– Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) –
Get started
Create a free account to read the full story.